We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01180907
First Posted: August 12, 2010
Last Update Posted: July 31, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
  Purpose
The purpose of the study is to determine whether positron emission tomography using the new imaging agent 18F-FAC can be used for imaging cancer and/or inflammation.

Condition
Cancer Inflammation

Study Type: Observational
Official Title: The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases: A Pilot Study

Further study details as provided by Jonsson Comprehensive Cancer Center:

Enrollment: 10
Study Start Date: November 2007
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
patients with cancer
patients with autoimmune diseases
healthy subjects

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
patients with cancer, autoimmune diseases and healthy subjects
Criteria

Inclusion Criteria:

  • > 18 years of age
  • women of childbearing potential will undergo a pregnancy test free of charge
  • patients with cancer or autoimmune diseases or healthy subjects
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01180907


Locations
United States, California
UCLA
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Principal Investigator: Christiaan Schiepers, M.D. Ph.D University of California, Los Angeles
  More Information

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT01180907     History of Changes
Other Study ID Numbers: 07-07-071
DE-PS02-08ER-08-01 ( Other Grant/Funding Number: Department of Energy )
CIRMNo. RT1-01126-1 ( Other Grant/Funding Number: California Institute for Regenerative Medicine )
10-000269 ( Other Identifier: UCLA Medical IRB#2 )
First Submitted: August 11, 2010
First Posted: August 12, 2010
Last Update Posted: July 31, 2012
Last Verified: July 2012

Keywords provided by Jonsson Comprehensive Cancer Center:
18F-FAC
imaging
cancer
inflammation
PET

Additional relevant MeSH terms:
Inflammation
Pathologic Processes